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ABSTRACT 
Objective: Estrogen receptor (ER) is over-expressed in 70% of breast cancers. The ER has two isoforms, ERα and ERβ. The ER ligand binding 
domain (LBD) has been the target for hormone-responsive breast cancer. Due to tissue-specific effects currently available drugs for hormone 
positive breast cancer presents serious limitation. The dynamic and plastic nature of ER LBD plays a crucial role in ligand design that discriminates 
between the ER subtypes. Agents that selectively target ER isoform are a formidable challenge to researchers. The chromone scaffold is a privileged 
scaffold for exploration of anticancer agents. The objective of the present study was to evaluate the anticancer activity of a small library of 2-
vinylchromones in human breast cancer cell lines MCF-7 and MDA-MB-231. 
Methods: The compounds were synthesized by the reported procedures. Docking studies of the substituted 2-vinylchromone was performed using 
GLIDE tool in Maestro 8.0. The compounds were evaluated for anticancer activity against MCF-7 (ERα positive), MDA-MB-231 (ERβ positive) and 
MRC-5 (ERα, β negative) cell lines using MTT assay.  
Results: The in silico studies indicated that substituted 2-vinylchromones, 1(a-c) and 2(a-b) exhibited comparable docking score at LBD of ERα and 
ERβ. However, the binding affinity of the compounds for the allosteric binding site in ERβ was negligible. The dose-dependent studies using MTT 
assay depicted that compounds 1(a-c) and 2(a-b) exhibited anticancer activity in ERα positive cell line MCF-7 as compared to ERβ positive cell line 
MDA MB 231. The most potent anticancer activity was observed for compound 2b against MCF-7 cells with IC50
Conclusion: The present investigation indicated that 2-vinylchromone derivatives exhibited ER isoform selectivity and the presence of bulky group 
in 2-vinylchromones resulted in significantly higher cytotoxicity in ERα positive cell lines as compared to the ERβ positive cell line. 
 value of 15.625 μg/ml. 
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INTRODUCTION 
Chromones are an important class of oxygen-containing heterocyclic 
compounds. Synthetic and natural chromone derivatives possess 
important biological activities such as antitumor [1], antihepatotoxic 
[2], antioxidant [3], anti-inflammatory [4], antiallergic [5], estrogenic 
[6] and antibacterial [7] activities. The anticancer activity of 
chromones has also been related to its structural similarity with 
flavonoids.  
Several compounds such as quercetin, genistein, daidzein, apigenin, 
biochanin A, kaempferol and naringenin that have chromone 
scaffold are known to bind to ER isoforms. Genistein, apigenin and 
kaempferol have a higher binding affinity 20 to 30-fold more for ERβ 
than ERα as indicated by a solid-phase binding assay [8-9].  
The above literature precedence prompted us to investigate the 
docking and cytotoxicity of 2-vinylchromones on human breast 
cancer cell lines. Previous work in our own group had led to the 
synthesis of novel chromone derivatives such as 3,4-dihydro-2H-1-
benzopyran-3,4 dione 1(a-c) using NaBH4
MATERIALS AND METHODS 
 (unpublished results) and 
in another study E-3-aminochromen-4-one 2(a-b) were synthesized 
(unpublished results). Herein, we report the in silico studies of 
chromone derivatives along with an assessment of cytotoxic activity 
of the compounds on MCF-7, MDA-MB-231 and MRC-5 cells.  
Determination of anticancer activity 
MTT assay 
5x103 cells/well were seeded in 96-multiwell flat bottom microtitre 
plate and cultured overnight in a humidified atmosphere of 5% CO2 
at 37 °C. The test compounds were serially diluted to the wells. 
Different concentrations ranging from 125µg/ml to 0.98µg/ml were 
analyzed. The cells were incubated for 24 h with test compounds 
with 5% CO2 at  37 °C. After 24 h, 10 µl of MTT (5 mg/ml in 1X PBS) 
was added to each well. The cells were incubated for 3 h and the 
centrifuged at 1500 rpm for 10 min. The media were discarded and 
150 µl of DMSO was added to each well. Optical density was 
measured using a microplate reader at 570 nm with reference 
optical density at 630 nm. IC50
Docking methodology 
 values were calculated as the 
concentrations that show 50% inhibition of proliferation on the 
tested cell line. 
The compounds were modelled using the BUILD application of 
Maestro 8.0. The geometry was optimized by molecular mechanics 
using IMPACT in a dynamic environment using the standard TIP4P 
water model. The energy minimization was done using Optimized 
Potentials for Liquid Simulations 2005 (OPLS 2005) force field. 
Energy minimization was done using Polak-Ribier conjugate 
gradient and Truncated Newton conjugate gradient algorithms. The 
convergence threshold used was rms gradient of 0.01.  
Conformational models of the ligands were generated. Docking of 
the ligands was carried out using an extra precision (XP) method 
called GLIDE (Grid-based Ligand Docking with Energetics) for 
flexible ligand docking. The ligands were prepared for docking using 
LIGPREP from Schrodinger’s molecular modeling software [10]. The 
PDB entries chosen for the above studies were 2QTU, 2FSZ and 
3ERT. The ligand interaction map was used to study the interactions 
of novel molecules with the residues of ER.  
Statistical analysis 
The experimental data obtained for each set of the experiment were 
expressed as the mean of change±SEM and analyzed by one-way and 
two-way ANOVA followed by a bonferroni post-test. Level of 
significance was set to P≤ 0.05. All the statistical calculations were 
performed using the evaluation version of Graph Pad Prism 5.1 
statistical software. 
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RESULTS 
The synthesized compounds were evaluated for their binding 
affinity towards ERα and ERβ by docking studies. The PDB entry 
chosen for the docking studies were 2QTU [11], 2FSZ [12] and 3ERT 
[13]. The PDB entry 3ERT is a complex of ERα with hydroxy-
tamoxifen (HT). The selection of 2QTU entry was based on structural 
similarity of the synthesized ligands with benzopyranones. Native 
ERβ pdb entry is not available therefore 2FSZ was selected which is 
a complex of HT with ERβ. The compounds were modelled using the 
BUILD application of Maestro 9.6. The energy minimization was 
performed using optimized potentials for liquid simulations 2005 
(OPLS 2005) force fields. In case of ERβ isoform, the docking studies 
were performed at the cognate site (2FSZ-101) as well as the 
allosteric binding site (2FSZ-103) of HT. The docking score of 
compounds 1(a-c) and 2(a-b) are indicated in table 1.  
The docking studies indicated that 1(a-c) and 2(a-b) exhibited 
comparable docking score at LBD of ERα and ERβ. However, the 
binding affinity of the compounds for the allosteric binding site in 
ERβ [12] was negligible. Amongst the analogues synthesized, best 
docking score for ERα was exhibited by compound 3-(butylamino)-
2-[(E)-2-(2-methoxyphenyl) ethenyl]-4H-chromen-4-one (2b) 
containing aminoalkyl group and 2-[2-(2-methoxy phenyl)ethyl]-
3,4-dihydro-2H-1-benzopyran-3,4 dione (1b) having a keto group at 
C-3 position. A comparison of the ligand interaction map 
represented in fig. 1 indicated that majority of the poses obtained for 
2b share the following common residues: Glu 353, Arg 394, Trp 383, 
Ala 350, Met 343, Leu 391, Ile 424, Leu 525, Leu 346, Leu 387 as 
compared with HT. Compound 2b also depicted other significant 
interactions with the following residues: Asp 351, Leu 349, Leu 354, 
Leu 536, Met 528, Thr 347, His 524, Leu 428, Met 388, Leu 384, Phe 
404, Ala 350. 
 
Table 1: Docking score and glide energy of the compounds 1(a-c) and 2(a-b) against ERα and ERβ 
S. No. Compound Structure 3ERT 2QTU 2FSZ (101) 2FSZ (103) 
   
 



























1  1a 
 
-5.19 -36.75 -7.8 -40.29 -6.57 -34.87 -3.42 -23.76 
2 1b 
 
-7.1 -27.4 -7.78 -38.64 -6.7 -36.56 -4.25 -29.98 
3 1c 
 
-6.14 -26.81 -6.03 -30.17 -5.23 -27.11 -3.42 -20.63 
4 2a 
 
-6.4 -34.35 -3.09 -21.86 -6.83 -43.35 -4.61 -30.49 
5 2b 
  
-8.27 -55.59 -3.87 -24.97 -5.84 -39.08 -3.39 -26.98 
 
3ERT is a complex of ERα with HT. 2QTU pdb entry is a complex of benzopyranones with ERβ. 2FSZ is a complex of HT with ERβ where docking 
studies performed at the cognate site of HT was labeled as 2FSZ-101 and the allosteric binding site was labeled as 2FSZ-103. 
 
The glide energy of the compound 1b and 2b with ERα was found to 
be -27.40Kcal/mol and -55.59Kcal/mol with -7.01 and -8.27 docking 
score. Fig. 1 (A and B) illustrates the interaction of compound 1b and 
2b with amino acid residues of ERα (PDB ID 3ERT). 
The dose-dependent studies using MTT assay depicted that 
compounds 1(a-c) and 2(a-b) exhibited anticancer activity in 
ERα positive cell line MCF-7 as compared to ERβ positive cell 
line MDA-MB-231. The compound 1b, 2a and 2b exhibited 
anticancer activity in ERα positive cell line. Amongst them 
compound 2b was most potent. Remarkable differences in the 
IC 50 value were seen for 1b, 2a and 2b in MCF-7 and MDA-MB-
231. The IC 50  value for 1b, 2a, 2b were 62.5μg/ml, 31.25μg/ml 
and 15.625μg/ml, respectively in MCF-7 cell line. All the 
compounds exhibited an IC 50  value of more than 125μg/ml in 
MDA-MB-231 cell line as indicated in table 2.
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Table 2: Comparative IC50
Compound 
 value of compounds in MCF-7 and MDA-MB-231 cell lines 
IC50 IC-MCF-7 (μg/ml) 50-MDA-MB-231 (μg/ml) 
1a 125 >125 
1b 62.5 >125 
1c >125 >125 
2a 31.25 >125 




Fig. 1: [A] Interactions of compound 1b; [B] Interactions of compound 2b 
 
The docking results of compound 1b, 2a and 2b on ERβ (PDB ID 2FSZ) on the other hand did not exhibit interactions with the significant residues in 
the ERβ LBD. The results are presented in fig. 2. 
 
   
[A] [B] [C] 
Fig. 2: [A] Interactions of compound 1b; [B] Interactions of compound 2a; [C] Interactions of compound 2b 
 
The three-dimensional structure of ERα docked with compound 1b and 2b are represented in fig. 3 which also displays the superimposition of 




Fig. 3: [A] Three-dimensional structure of ERα docked with compound 1b; [B] Three-dimensional structure of ERα docked with compound 
2b; where HT is represented in red and compound 1b and 2b in green 
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In an attempt to corroborate the results of docking studies for compounds 1(a-c) and 2(a-b) MTT assay were performed in ERα and ERβ positive 
cell lines. The cell lines chosen for the studies were MCF-7 (ERα positive), MDA-MB-231 (ERβ positive) and MRC-5 (ERα,β negative). The results of 
these studies are depicted in fig. 4.  
 
 
Fig. 4: Comparative graph for 1(a-c) and 2(a-b) compounds with % change in optical density in respective cell lines plotted against 
different concentrations of compounds. The data are mean±SEM from 2 samples for each group and analyzed by two-way ANOVA followed 
by Bonferroni Post-test where * P<0.01 significant from control 
 
DISCUSSION 
The LBD of ERα and ERβ has 60% homology [14]. The dynamic and 
plastic nature of ER LBD plays a crucial role in ligand design that 
discriminates between the ER subtypes. 
The interior of the ligand binding pocket of ERα and ERβ have been 
reported to have 22-24 residues which are identical and involved in 
interactions with ligands [15]. The two pockets are however 
different in size and flexibility and this aspect is crucial for the 
development of selective subtype agents [16]. 
Apart from this the discovery of allosteric binding pocket in the 
coactivator groove of ERβ further provides avenues for identification 
of agents known as coactivator binding inhibitors [12, 17]. In the 
present exploratory work we have attempted to identify ER isoform-
selective compounds from a small library of 2-vinylchromones. For 
this purpose docking studies have been carried at both ERα and ERβ 
LBD and allosteric binding pocket of ERβ. The findings of docking 
studies have been correlated with MTT assay on ERα, ERβ and ER α, 
β negative cell lines.  
The in silico studies revealed that the synthesized compounds 
preferentially binds to the ligand binding domain of ERα and ERβ 
with a comparable docking score except for 2b which exhibits 
preferential docking to ERα. It was also found that these compounds 
exhibited poor binding to the allosteric binding site of ERβ. Highest 
docking score amongst the series was also observed for compound 
2b. Prominent interacting residues including Glu 353, Arg 394 and 
Asp351 as compared to HT clearly indicate high-affinity binding 
which is further corroborated with a high docking score of 2b. A 
comparison of docking residues of ERβ, on the other hand, did not 
reveal an interaction with these residues. 
Further, the evaluation of the cytotoxic activity indicated that these 
novel compounds have exhibited significant cytotoxicity in ERα 
positive cell line instead of ERβ positive cell line. Studies on ligands 
such as genistein have clearly established that although it exhibits 
similar binding mode when complexed to ERα and ERβ [18] it exhibits 
40-fold selectivity for ERβ [19]. Similarly, electron density maps of HT 
complexed to ERβ indicate one of the HT molecules is located in the 
cognate ligand binding pocket with a confirmation indistinguishable 
from ERα/HT structure [20]. However; a comparison of IC50
In our studies, it was observed that in all cases the chromones with 
methoxy substitution 1b, 2a and 2b exhibited the highest 
cytotoxicity. The presence of a bulky aminoalkyl group at C-3 of the 
chromone ring as compared to the keto group as in the case of 2a 
and 2b respectively led to significantly higher cytotoxicity. Further; 
structure-activity relationship studies will help to correlate 
contribution of long chain aminoalkyl substitution to cytotoxicity. 
 values of 
HT in ERα and ERβ indicates ERα selectivity [21]. These observations 
suggest the involvement of different residues of ERα and ERβ LBD that 
may contribute towards isoform selectivity.  
CONCLUSION 
2-vinylchromone derivatives exhibited higher cytotoxicity in ERα 
positive cell lines as compared to the ERβ positive cell line. Our 
results also indicated that these derivatives exhibited ER isoform 
selectivity and presence of bulky group as in the case of 2a and 2b 
resulted in a significant increase in cytotoxic activity. 
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